San Diego – May 13, 2022 – Cooley advised Neurocrine Biosciences, a neuroscience-focused biopharmaceutical company, on its agreement to lease a new 535,000-square-foot space at the Aperture Del Mar campus in San Diego’s Carmel Valley, which will become the company’s corporate headquarters. David Crawford led the Cooley team advising Neurocrine.
The 13.5-year lease of four buildings on the campus was recognized by the San Diego Business Journal as “one of the biggest life science leases ever for the San Diego County market.” Neurocrine plans to begin moving into its new space in 2023.
“This will allow us to double our research and development organization. That’s our desire and our growth expectations,” Matt Abernethy, Neurocrine’s chief financial officer, said in a statement to the San Diego Business Journal.
Neurocrine’s purpose is to relieve suffering for people with great needs, but few options. The company is dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Neurocrine’s diverse portfolio includes US Food and Drug Administration-approved treatments for tardive dyskinesia, Parkinson’s disease, endometriosis and uterine fibroids, as well as more than a dozen mid-to-late-stage clinical programs in multiple therapeutic areas.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 1,500 lawyers across 17 offices in the United States, Asia and Europe.